Molecular structure of LY3214996, CAS Number: 1951483-29-6
LY3214996 (CAS 1951483-29-6)
Alternate Names:
Temuterkib; 5,6-dihydro-6,6-dimethyl-2-[2-[(1-methyl-1H-pyrazol-5-yl)amino]-4-pyrimidinyl]-5-[2-(4-morpholinyl)ethyl]-4H-thieno[2,3-c]pyrrol-4-one
CAS Number:
1951483-29-6
Molecular Weight:
453.6
Molecular Formula:
C22H27N7O2S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LY3214996 (CAS 1951483-29-6) References
- Blocking VEGF signaling augments interleukin-8 secretion via MEK/ERK/1/2 axis in human retinal pigment epithelial cells. | Zhou, LB., et al. 2020. Int J Ophthalmol. 13: 1039-1045. PMID: 32685389
- LncRNA BANCR Attenuates the Killing Capacity of Cisplatin on Gastric Cancer Cell Through the ERK1/2 Pathway. | Miao, X., et al. 2021. Cancer Manag Res. 13: 287-296. PMID: 33469371
- LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. | Ma, Y., et al. 2021. Int J Med Sci. 18: 1456-1464. PMID: 33628103
- ERK and mTORC1 Inhibitors Enhance the Anti-Cancer Capacity of the Octpep-1 Venom-Derived Peptide in Melanoma BRAF(V600E) Mutations. | Moral-Sanz, J., et al. 2021. Toxins (Basel). 13: PMID: 33672955
- IL-27 Mediates Pro-Inflammatory Effects via the ERK Signaling Pathway During Preterm Labor. | Huang, D., et al. 2021. Front Immunol. 12: 709229. PMID: 34691022
- Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. | Lebedev, TD., et al. 2022. J Biol Chem. 298: 102226. PMID: 35787369
- Simultaneous determination of LY3214996, abemaciclib, and M2 and M20 metabolites in human plasma, cerebrospinal fluid, and brain tumor by LC-MS/MS. | Margaryan, T., et al. 2022. J Pharm Anal. 12: 601-609. PMID: 36105156
- Caveolae-associated protein 3 promotes adipogenic differentiation of porcine preadipocytes by promoting extracellular signal-regulated kinase phosphorylation. | Shi, M., et al. 2023. Anim Sci J. 94: e13822. PMID: 36922373
- Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma. | Flint, AC., et al. 2023. Clin Cancer Res. 29: 3438-3456. PMID: 37406085
- The ERK inhibitor LY3214996 augments anti-PD-1 immunotherapy in preclinical mouse models of BRAFV600E melanoma brain metastasis. | de Sauvage, MA., et al. 2024. Neuro Oncol. 26: 889-901. PMID: 38134951
Inhibitor of:
2210010C17Rik, 9430016H08Rik, AKIP, APEG1, ARRDC2, BC035044, BNC1, BRSK2, C10orf122, C11orf55, C12orf60, C1orf122, C2orf60_1110034B05Rik, C5orf24, Capicua, CCDC102B, CCDC117, CCDC13, CCDC157, CCDC39, CCDC71, CCDC82, CECR4, CECR6, CEL, Cerebellin 2, CHIC1, EAT2, Eos, ERK 1, ERK 2, ERK 3, FAM23A, FAM24A, FLJ35220, FLJ46321, FLRT2, GABP-α, GIMAP8, GLT1D1, Gm19402, IER5L, IZUMO4, KPL2, LOC100041259, LOC401317, LOC644978, LOC645941, LOC727903, LOC728110, LOC729159, M13 Major Coat Protein, MANBAL, MLTK, Mpk1, MS4A3, MS4A4E, MS4A5, MYADM, MYT1L, NET-6, Olfr368, Olfr539, Olfr908, Olfr909, Olfr91, Olfr910, Olfr912, Olfr913, Olfr914, Olr264, Olr74, ORF67, OTTMUSG00000005148, OTTMUSG00000005215, OTTMUSG00000005288, OTTMUSG00000005304, OTTMUSG00000010009, OTTMUSG00000010327, OTTMUSG00000017976, OTTMUSG00000018258, Pira2, PNMAL2, Porimin, PRR23A, Rap 1B, RERGL, RGPD4, RIM-BP3C, Rsk-3, SCOP, Scpppq1, SPHAR, SPINK13, SPOCD1, SSXB1, TESSP-1, TMEM214, TNRC6C, VGF, ZDHHC9, ZFP936, ZFP963, and ZNF732.Activator of:
ALY, C030019I05Rik, C23, C330006A16Rik, CD69, TMCO4, TTK, and VPS45.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LY3214996, 5 mg | sc-507299 | 5 mg | $265.00 |